Moderna Q2: Low Revenue, Norovirus Setback, but Cost Cuts and Flu Shot Loom Large

What happened

Moderna reported Q2 2026 revenue of just $0.1 billion amid shrinking COVID sales, yet improved its operating expense outlook by $0.2 billion and raised year-end cash guidance to $4.7–5.2 billion. The upcoming August 5 PDUFA decision on the flu vaccine remains a critical catalyst following a unanimous VRBPAC vote, though label scope will determine commercial success. A Phase 3 failure of the norovirus vaccine candidate reduces pipeline diversification, reinforcing the company’s dependence on respiratory products. Management reiterated expectations for up to 10% revenue growth in 2026, signaling confidence in the respiratory franchise even as near-term sales remain anemic. Investors now face a cleaner balance sheet and an imminent regulatory binary event, but with a thinner pipeline to sustain long-term growth.

Implication

Moderna's Q2 shows progress on costs and cash preservation, keeping the flu approval as a near-term stock mover. However, the norovirus failure reduces pipeline optionality, amplifying the importance of the flu label and commercial uptake. If the FDA grants a broad label, the improved cash position could support a sustainable launch, but a narrow label or further pipeline misses could pressure shares given the concentrated risk profile. Maintain WAIT rating with a focus on the August 5 PDUFA and subsequent commercial traction.

Thesis delta

The investment thesis shifts slightly: narrower pipeline risk is offset by better-than-expected cost control and cash runway. Flu approval remains the lynchpin, but investors must now discount the loss of norovirus as a second major catalyst.